These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31320330)

  • 1. The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis.
    Cassels A; Law MR
    CMAJ Open; 2019; 7(3):E472-E477. PubMed ID: 31320330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis.
    Miregwa BN; Holbrook A; Law MR; Lavis JN; Thabane L; Dolovich L; Wilson MG
    CMAJ Open; 2022; 10(3):E848-E855. PubMed ID: 36167420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
    Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
    Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.
    Scobie AC; Mackinnon NJ
    Healthc Policy; 2010 Feb; 5(3):100-14. PubMed ID: 21286272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a value-based formulary in three chronic disease cohorts.
    Yeung K; Basu A; Marcum ZA; Watkins JB; Sullivan SD
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S46-S53. PubMed ID: 29648740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis.
    CMAJ Open; 2019; 7(3):E510. PubMed ID: 31431482
    [No Abstract]   [Full Text] [Related]  

  • 12. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Income-based drug coverage in British Columbia: the impact on private and public expenditures.
    Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e129-53. PubMed ID: 19305696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a closed formulary on prescription drug use and costs.
    Motheral BR; Henderson R
    Inquiry; 1999-00 Winter; 36(4):481-91. PubMed ID: 10711322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Features of employment-based health plans.
    Fronstin P
    EBRI Issue Brief; 1998 Sep; (201):1-21. PubMed ID: 10345788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones.
    Hashim S; Gomes T; Juurlink D; Hellings C; Mamdani M
    J Popul Ther Clin Pharmacol; 2013; 20(3):e238-42. PubMed ID: 24141901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.
    Glazer J; Huskamp HA; McGuire TG
    Forum Health Econ Policy; 2012 Mar; 15(2):. PubMed ID: 23372543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.